According to US Food and Drug Administration (USFDA), Wockhardt USA Inc, a subsidiary of Mumbai-based firm is voluntarily recalling 8,712 bottles of the drug in the American market.
The recall is due to the "failure of dissolution test observed at three month time point", USFDA said.
The nationwide recall was initiated on April 10. The 100 mg tablets in 100-count bottles were manufactured by Wockhardt Ltd and distributed in the US market by Wockhardt USA Inc, it added.
The withdrawal was classified as a Class-II recall, which the FDA defines as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
Comments from Wockhardt could not immediately be obtained.
Wockhardt scrip closed at Rs 573.55, up 0.16 per cent, on the BSE.